NDA 216340 · Bristol
Krazati
Adagrasib · Oral
NovelBreakthrough therapyAccelerated approvalOrphanCDER novel approval, Dec 12, 2022: To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Dec 12, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
38
5 Phase 3, 10 recruiting
FAERS reports
1,134
878 serious, 349 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 31, 2026.
KRAZATI, as a single-agent, is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test [see Dosage and Administration (2.1) ] , who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial. KRAZATI is an inhibitor of the RAS GTPase family indicated for: Non-small cell lung cancer (NSCLC)* • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1 ) *This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in confirmatory trials.
Mechanism: Adagrasib is an irreversible inhibitor of KRAS G12C that covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state that prevents downstream signaling without affecting wild-type KRAS protein. Adagrasib inhibited tumor cell growth and viability in cells harboring KRAS G12C mutations and resulted in tumor regression in KRAS G12C-mutated tumor xenograft models with minimal off-target activity.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 21, 2024 Supplement 5 · Efficacy · priority review Breakthrough therapyAccelerated approvalOrphanLabelLetterReview
- Dec 12, 2022 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- KRAZATI · ADAGRASIB 200MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Adagrasib" as an intervention, any sponsor and status, largest first.
- Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active, not recruiting
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT03785249 · 731 participants · Start Jan 15, 2019 · Primary completion Jun 23, 2026
Drug: MRTX849; Pembrolizumab and 2 more · For: Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 222 sites in all
- A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)Pivotal-lookingRecruiting
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT06875310 · 630 participants (planned) · Start Apr 24, 2025 · Primary completion Sep 7, 2029
Drug: Adagrasib; Pembrolizumab and 4 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Birmingham, Alabama; Springdale, Arkansas; Fullerton, California · 317 sites in all
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Pivotal-lookingRecruiting
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT04613596 · 626 participants (planned) · Start Dec 2, 2020 · Primary completion Oct 31, 2028
Drug: Adagrasib; Adagrasib and 3 more · For: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
Sites: Goodyear, Arizona; Prescott Valley, Arizona; Safford, Arizona · 776 sites in all
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialPivotal-lookingRecruiting
City of Hope Medical CenterAcademic, hospital or other
NCT07288034 · 535 participants (planned) · Start May 1, 2026 · Primary completion Oct 8, 2028
Drug: Adagrasib; Anti-PD-L1 Monoclonal Antibody and 5 more · For: Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
Sites: Goodyear, Arizona; Corona, California; Duarte, California · 13 sites in all
- Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)Pivotal-lookingActive, not recruiting
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT04793958 · 461 participants · Start Jun 24, 2021 · Primary completion Jan 16, 2026
Drug: MRTX849; Cetuximab and 2 more · For: Advanced Colorectal Cancer; Metastatic Colorectal Cancer
Sites: Alabaster, Alabama; Bessemer, Alabama; Birmingham, Alabama · 419 sites in all
- Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationPivotal-lookingActive, not recruiting
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT04685135 · 453 participants · Start Feb 23, 2021 · Primary completion Dec 30, 2023
Drug: MRTX849; Docetaxel · For: Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer
Sites: Cerritos, California; Duarte, California; Glendale, California · 380 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06764771 · 437 participants (planned) · Start Mar 25, 2025 · Primary completion Oct 15, 2027
Drug: BMS-986488; Adagrasib and 2 more · For: Advanced Malignant Tumors
Sites: Hackensack, New Jersey; Allentown, Pennsylvania; Germantown, Tennessee · 8 sites in all
- A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06497556 · 338 participants · Start Sep 23, 2024 · Primary completion May 19, 2026
Drug: Divarasib; Sotorasib and 1 more · For: Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer
Sites: Gilbert, Arizona; Los Angeles, California; San Francisco, California · 151 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death306
- diarrhoea133
- hospitalisation116
- nausea106
- off label use95
- vomiting90
- asthenia72
- fatigue63
- decreased appetite48
- dehydration43
- dyspnoea40
- acute kidney injury36
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 6 |
| 2023 | 365 |
| 2024 | 385 |
| 2025 | 201 |
| 2026 | 176 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Krazati (Adagrasib)
2024 spending
$69.7M
Beneficiaries
1,042
3,873 claims
Per beneficiary
$66,903
$119.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $22,747,939 |
| 2024 | $69,712,635 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.
Yaeger R, Weiss J, Pelster MS, et al. · N Engl J Med 2023 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.
Yaeger R, Uboha NV, Pelster MS, et al. · Cancer Discov 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.
Barlesi F, Yao W, Duruisseaux M, et al. · Lancet 2025 · Clinical Trial, Phase III, Multicenter Study
- Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
Jänne PA, Riely GJ, Gadgeel SM, et al. · N Engl J Med 2022 · Clinical Trial, Phase II
- Adagrasib Response Remains Strong in NSCLC.
· Cancer Discov 2022 · Clinical Trial
- First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).
Ou SI, Jänne PA, Leal TA, et al. · J Clin Oncol 2022 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.